Several clinical trials attempted to identify novel treatment options for advanced gastroesophageal tumours in first, second and further lines. Although results of targeted therapy regimens were mainly disappointing, novel immunotherapy agents showed promising activity, which led to their approval in second and third lines in many countries. This review focuses on the results of recent clinical trials investigating novel agents including targeted therapies, immunotherapy components and chemotherapies and discuss their current impact as well as current approval status on the treatment armamentarium of advanced gastroesophageal tumours.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7072704 | PMC |
| http://dx.doi.org/10.3390/cancers12020301 | DOI Listing |
Publication Analysis
Top Keywords
advanced gastroesophageal
12
gastroesophageal tumours
12
treatment options
8
options advanced
8
clinical trials
8
tumours mature
4
mature current
4
current practice?
4
practice? clinical
4
trials attempted
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!